Verastem to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Verastem, Inc., (NAS: VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at several upcoming conferences. The presentation details are as follows:
2013 BIO International Convention Business Forum on April 22, 2013, at 2:15pm CT in the Chicago Bears room of McCormick Place in Chicago, IL
Needham 12th Annual Healthcare Conference on May 1, 2013, at 12:10pm ET at the Westin Grand Central in New York, NY
A webcast of the Needham conference presentation can be accessed by visiting the investors section of the Company's website at www.verastem.com. A replay of the webcast will be archived on the Verastem website for two weeks following the presentation date.
About Verastem, Inc.
Verastem, Inc. (NAS: VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit www.verastem.com.
Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.
KEYWORDS: United States North America Massachusetts
The article Verastem to Present at Upcoming Conferences originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.